
New (and pricey) hepatitis C medicines, such as Harvoni and Sovaldi, are living up to their promise and greatly reducing patients’ odds for liver cancer and death, a new French study finds. The news came as little surprise to one U.S. liver expert. The advent of this class of drugs “has led to almost universal… read on >